文献速递湿疹皮炎与荨麻疹

度普利尤单抗临床试验中的结膜炎分析

Conjunctivitis in dupilumab clinical trials.
PubMed 文献 · Br J Dermatol · 2019-05-07

该分析评估了度普利尤单抗在特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉和嗜酸性食管炎随机安慰剂对照试验中的结膜炎发生情况。在多数特应性皮炎试验中,度普利尤单抗组结膜炎发生率高于安慰剂组,且与基线特应性皮炎严重程度和既往结膜炎史相关;在其他2型疾病试验中发生率很低且与安慰剂相似。

要点

  • 特应性皮炎试验中度普利尤单抗组结膜炎发生率高于安慰剂,多為轻中度。
  • 基线特应性皮炎严重程度和既往结膜炎史与结膜炎发生风险增加相关。
  • 哮喘、慢性鼻窦炎伴鼻息肉和嗜酸性食管炎试验中结膜炎发生率低,度普利尤单抗未增加风险。

核心结论

  • 在多数特应性皮炎试验中,度普利尤单抗治疗组结膜炎发生率高于安慰剂组。
  • 在哮喘、慢性鼻窦炎伴鼻息肉和嗜酸性食管炎试验中,结膜炎发生率总体很低,度普利尤单抗与安慰剂相似。
  • 特应性皮炎中结膜炎发生与特应性皮炎严重程度和既往结膜炎史相关。

研究设计与样本

  • 评估了度普利尤单抗在特应性皮炎(n=2629)、哮喘(n=2876)、慢性鼻窦炎伴鼻息肉(n=60)和嗜酸性食管炎(n=47)的随机安慰剂对照试验。

主要发现

  • 在多数特应性皮炎试验中,度普利尤单抗组结膜炎发生率高于安慰剂组。
  • 较高的基线特应性皮炎严重程度和既往结膜炎史与结膜炎发生率增加相关。
  • 结膜炎多为轻中度,多数病例在治疗期间恢复或缓解,仅2例患者因结膜炎或角膜炎永久停用度普利尤单抗。
  • 常见治疗包括眼科皮质类固醇、抗生素和抗组胺药或肥大细胞稳定剂。
  • 在哮喘和慢性鼻窦炎伴鼻息肉试验中,度普利尤单抗和安慰剂组的结膜炎发生率均低于特应性皮炎试验,且度普利尤单抗未增加发生率;嗜酸性食管炎试验中无患者发生结膜炎。

关键数值与推荐

  • 特应性皮炎试验样本量n=2629,哮喘n=2876,慢性鼻窦炎伴鼻息肉n=60,嗜酸性食管炎n=47。
  • 仅2例患者因结膜炎或角膜炎永久停用度普利尤单抗。

临床怎么用

  • 在特应性皮炎患者中使用度普利尤单抗时,应关注基线疾病严重程度和既往结膜炎史以评估结膜炎风险。
  • 多数结膜炎为轻中度,可通过对症治疗管理,永久停药罕见。

局限性

  • 结膜炎的病因和治疗仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate-to-severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Japan whose AD is uncontrolled with existing therapies, for patients with moderate-to-severe AD in Europe who are candidates for systemic therapy and for patients aged ≥ 12 years for maintenance treatment of moderate-to-severe asthma uncontrolled with their current medicines. AD trials have reported increased incidence of conjunctivitis for dupilumab vs. placebo. OBJECTIVES: To characterize further the occurrence and risk factors of conjunctivitis in dupilumab clinical trials. METHODS: We evaluated randomized placebo-controlled trials of dupilumab in AD (n = 2629), asthma (n = 2876), chronic rhinosinusitis with nasal polyps (CRSwNP) (n = 60) and eosinophilic oesophagitis (EoE) (n = 47). RESULTS: In most AD trials, dupilumab-treated patients had higher conjunctivitis incidence than placebo controls. Higher baseline AD severity and previous history of conjunctivitis were associated with increased conjunctivitis incidence. Conjunctivitis was mostly mild to moderate. Most cases recovered or resolved during the treatment period; two patients permanently discontinued dupilumab due to conjunctivitis or keratitis. Common treatments included ophthalmic corticosteroids, antibiotics, and antihistamines or mast cell stabilizers. Most cases were diagnosed by the investigators. In asthma and CRSwNP trials, the incidence of conjunctivitis was lower for both dupilumab and placebo than in AD trials; dupilumab did not increase the incidence compared with placebo. In the EoE trial, no patients had conjunctivitis. CONCLUSIONS: Conjunctivitis was more frequent with dupilumab treatment in most AD trials. In dupilumab trials in other type 2 diseases, incidence of conjunctivitis was overall very low, and was similar for dupilumab and placebo. In AD, the incidence of conjunctivitis was associated with AD severity and prior history of conjunctivitis. The aetiology and treatment of conjunctivitis in dupilumab-treated patients require further study. What's already known about this topic? Ocular disorders, including allergic conjunctivitis, are common in patients with atopic dermatitis (AD). In most dupilumab AD trials, dupilumab-treated patients had higher conjunctivitis incidence than those receiving placebo. Most cases were mild to moderate and recovered or were recovering during study treatment; study treatment discontinuation due to conjunctivitis was rare. Conjunctivitis incidence was very low and similar for dupilumab and placebo in clinical trials in asthma, chronic rhinosinusitis with nasal polyps and eosinophilic oesophagitis. What does this study add? This analysis confirms and extends the results of the individual clinical trials. Baseline disease-related factors, including AD severity, prior conjunctivitis history and certain biomarkers (thymus and activation-regulated chemokine, IgE, eosinophils), were associated with increased incidence of conjunctivitis. Patients who responded well to dupilumab had reduced incidence of conjunctivitis. Further study is needed to elucidate the aetiology and treatment of conjunctivitis in dupilumab-treated patients with AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019. PMID: 30851191. doi:10.1111/bjd.17869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。